Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (8158)	12/31/1998 4:35:00 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

Bob, nice find. Here is cut and paste providing a bit of comments on BPI. BPI protein domain III analogs. The bactericidal and permeability-increasing (BPI) protein is a cationic protein stored principally in the azurophilic granules of neutrophils (43). Several potent antifungal peptides with activity against Candida spp., C. neoformans, and A. fumigatus were derived from BPI protein functional domain III (109). These constructs produced significant, dose-dependent reductions in the numbers of C. albicans CFU in the kidney and significant protection from mortality in murine candidiasis models (5). Three small synthetic peptides (XMP.284, XMP.366, and XMP.391) based on BPI protein domain III were found to be fungicidal for several Candida species, while subinhibitory concentrations of these peptides enhanced the anti-Candida activities of fluconazole (78). XMP.391 was effective against murine disseminated aspergillosis and enhanced the effectiveness of amphotericin B (4).